Lithium Fails to Improve Long-COVID Symptoms

Broadcast Message

Lithium is ineffective for long-COVID syndrome linked to the SARS-CoV-2 Spike protein, lacking any mechanism to address it. A recent randomized trial showed no benefit from low-dose lithium, as it didn't consider key factors like Spike antibody levels and COVID-19 vaccine details. Overall, adjunctive therapies might assist within the McCullough Protocol for Spike detoxification.

Link

https://petermcculloughmd.substack.com/p/lithium-fails-to-improve-long-covid

Lithium Fails to Improve Long-COVID Symptoms Ignoring Spike Protein Is Fatal Flaw in Long-COVID Research Mon, 07 Oct 2024 09:05:43 GMT https://petermcculloughmd.substack.com/p/lithium-fails-to-improve-long-covid By Peter A. McCullough, MD, MPH

Lithium has joined the long-list of various drugs and supplements that have failed to improve long-COVID syndrome caused by the SARS-CoV-2 Spike protein. A common theme is forming: if the product does not either help elminate Spike or block its damaging effects on the body, then it is unlikely to play a role in the management of post-acute sequelae after SARS-CoV-2 and the Spike producing COVID-19 vaccines.

Michael Nehls, MD, PhD, proposed lithium as a “cure” for long-COVID syndrome in his book The Indoctrinated Brain and on his breakout Tucker Carlson interview. I was immediately skeptical and never used it in practice since there was no mechanism for the psychiatric drug to influence the Spike protein which is the underlying cause of the syndrome.

Guttuso T, Zhu J, Wilding GE. Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(10):e2436874. doi:10.1001/jamanetworkopen.2024.36874

A randomized trial of low dose lithium by Guttuso et al show no signal of benefit. The authors failed to categorize antibodies against the Spike protein or its determinants including the number of COVID-19 illness episodes and the COVID-19 vaccine brand, dates given of primary series and boosters. The study was a bust.

It is unlikely that any product in the area of inflammation, oxidative stress, neurotransmission, or metabolism will play a role alone in management. However it is possible that adjunctive therapies could help symptoms in patients on McCullough Protocol Base Spike Detoxification. That is the reason why the protocol has “base” in its name.

Courageous Discourse™ with Dr. Peter McCullough & John Leake is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Please subscribe to Courageous Discourse as a paying ($5 monthly) or founder member so we can continue to bring you the truth.

Peter A. McCullough, MD, MPH

President, McCullough Foundation